Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Description

This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

Conditions

Myasthenia Gravis, Generalized

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG)

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Condition
Myasthenia Gravis, Generalized
Intervention / Treatment

-

Contacts and Locations

Carlsbad

Profound Research, Carlsbad, California, United States, 92011

Irvine

University of California Irvine, Irvine, California, United States, 92697

Aurora

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States, 80045

Boca Raton

SFM Clinical Research, LLC, Boca Raton, Florida, United States, 33487

Orlando

Neurology Associates, P.A., Orlando, Florida, United States, 32751

Tampa

University of South Florida, Tampa, Florida, United States, 33612

Augusta

University of Augusta, Augusta, Georgia, United States, 30912

Kansas City

University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States, 66160

Amherst

Dent Neurologic Institute, Amherst, New York, United States, 14226

Chapel Hill

University of North Carolina, Chapel Hill, North Carolina, United States, 27599

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patient must be at least 18 years of age.
  • * Patient must have Generalized Myasthenia Gravis at the time of screening.
  • * Concomitant immunosuppressive drugs must be deemed necessary by the investigator.
  • * Seronegative Patients are included
  • * Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient.
  • * Patient is pregnant or lactating.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Cartesian Therapeutics,

Study Record Dates

2026-03-31